+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Effects of long-term oxygen therapy on mortality and morbidity



Effects of long-term oxygen therapy on mortality and morbidity



Respiratory Care 45(1): 105-118



In general, based on the above studies of the effects of supplemental oxygen on reducing mortality and improving sleep and exercise function in certain patient groups, patients whose disease is stable on a full medical regimen with PaO2 < or = 55 mm Hg (SaO2 < or = 88%) should be considered for LTOT. Patients with PaO2 of 55-59 mm Hg with signs of tissue hypoxemia (i.e., cor pulmonale, polycythemia, impaired cognition) should also be considered for LTOT. Oxygen therapy should also be considered for those who desaturate during sleep or exercise. These guidelines have been adopted by Medicare as reimbursement criteria and have also been endorsed by the American Thoracic Society. Indications for LTOT endorsed by the American Thoracic Society and published in the "Standards for the Diagnosis and Care of Patients with COPD" are shown in Table 6. More research is required to investigate the use of supplemental oxygen in patients who suffer nocturnal desaturation but do not have signs of end organ dysfunction, those who have an improvement in dyspnea with supplemental oxygen, and in normoxemic patients with impaired exercise performance who improve while inspiring supplemental oxygen.

(PDF emailed within 1 workday: $29.90)

Accession: 045914640

Download citation: RISBibTeXText

PMID: 10771786


Related references

Effects of long term oxygen therapy on mortality and morbidity in chronic obstructive lung disease. Widimsky, J , J Herget And J Mlczoch (Ed ) Progress in Respiration Research, Vol 20 Pulmonary Circulation in Chronic Lung Diseases: Experimental And Clinical Approach; Meeting, Prague, Czechoslovakia, July 4-6, 1984 Vii+192p S Karger: Basel, Switzerland; New York, N Y , Usa Illus 55-59, 1985

Long-term oxygen therapy: mortality rate, short-term predictive mortality factors. Revue des Maladies Respiratoires 35(9): 939-947, 2018

Morbidity and mortality during long-term anticoagulant therapy. CIRCULATION 24(4 Pt 2): 907-908, 1961

Acute hypercapnic respiratory failure (AHRF): looking at long-term mortality, prescription of long-term oxygen therapy and chronic non-invasive ventilation (NIV). Clinical Medicine 12(2): 188, 2012

Neuropsychological effects of short-term discontinuation of oxygen therapy. Observations in patients with chronic hypoxemia who are receiving long-term oxygen therapy. Archives of Internal Medicine 146(8): 1557-1559, 1986

Long-term cardiac morbidity and mortality during dialysis therapy. Advances in Nephrology From the Necker Hospital 23: 311-330, 1994

Factors relating to morbidity and mortality of women on long-term estrogen therapy. Frontiers of Hormone Research 5: 40-52, 1977

Long-Term Effects of Childhood Obesity on Morbidity and Mortality. Hormone Research 55(Suppl. 1): 42-45, 2001

Long-term effects of childhood obesity on morbidity and mortality. Hormone Research 55 Suppl 1: 42-45, 2001

Long-term effects of cancer therapy in children – functional effects, late mortality and long-term follow-up. Paediatrics and Child Health 22(6), 2012

Long-term effects of prenatal x-ray of human females. III. Mortality and morbidity. American Journal of Epidemiology 114(3): 327-336, 1981

New ECG markers for predicting long-term mortality and morbidity in patients receiving cardiac resynchronization therapy. Journal of Electrocardiology 51(4): 637-644, 2018

Potential impact of long-term nucleoside therapy on the mortality and morbidity of active chronic hepatitis B. Hepatology 50(3): 743-751, 2009

Long term effects of propranolol on morbidity and mortality in patients with angina pectoris. Cardiovascular Medicine 2(3): 253-262, 1977

Saving lives: long-term morbidity and mortality trials with selective angiotensin receptor blocker therapy. Journal of the Renin-Angiotensin-Aldosterone System 1(2 Suppl.): S17-S20, 2007